Critical Outcome Technologies Inc.

Critical Outcome Technologies Inc.

June 11, 2008 18:01 ET

Critical Outcome Technologies Inc. Announces the Issuance of Stock Options

LONDON, ONTARIO--(Marketwire - June 11, 2008) - Critical Outcome Technologies Inc. (TSX VENTURE:COT) announced today, that at its Board meeting of June 10, 2008 the Board of Directors approved the granting of 335,679 stock options to its eight Directors under the Company's Stock Option Plan as a retainer for their service on the Board and its committees during fiscal 2008. The options vest immediately, have a life of five years and are exercisable at a price of $0.75 per share. The exercise price represents the closing price of the Company's common shares on June 9, 2008, as reported on the TSX Venture Exchange.

"The use of stock options to compensate the board members allows us to conserve our cash as we move forward with our drug development plans and demonstrates the Directors' belief and commitment to the company's future," advised company Chairman and CEO, Mr. John Drake.

About Critical Outcome Technologies Inc. (COTI)

COTI is formed around a unique computational platform technology called CHEMSAS®, which allows for the accelerated identification, profiling and optimization of targeted small molecules potentially effective in the treatment of human diseases for which current therapy is either lacking or ineffective. COTI's business is focused on the discovery and pre-clinical development of libraries of optimized lead molecules for the treatment of specific cancers, HIV and multiple sclerosis. Currently, five targeted libraries of lead compounds (small cell lung cancer, multiple sclerosis, HIV integrase inhibitors, colorectal cancer, and acute myelogenous leukemia in adults) are under active development.

For more information, please visit our website

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this news release.

Contact Information